European Archives - Page 781 of 1142 - European Medical Journal

Continue
1 Mins
6 Dec 2018

Preliminary Safety, Efficacy, and Pharmacokinetic and Pharmacodynamic Characterisation from GARNET, a Phase I Clinical Trial of the Anti-PD-1 Monoclonal Antibody TSR-042 in Patients with Recurrent or Advanced Microsatellite Instability-High Endometrial Cancer

At the European Society for Medical Oncology (ESMO) 2018 Congress, data from the ongoing Phase I clinical trial of the anti-programmed death…
8 Mins
6 Dec 2018

Prediction with Precision: Does TAILORx Make Chemotherapy a Personalised Treatment?

Adjuvant chemotherapy (CT) is commonly recommended to breast cancer patients following surgery. However, not all patients benefit from it, and the…
5 Mins
6 Dec 2018

Congress Feature from ESMO 2018

During this year’s ESMO Congress, the EMJ team attended the three hotly- anticipated Presidential Symposia chaired by ESMO President Prof Josep Tabernero…
1 Mins
6 Dec 2018

Patient Reports of Mouth Symptoms after Radiotherapy Treatment for Head and Neck Cancer: An International Survey

People with head and neck cancer frequently have symptoms that are caused by their disease or by their treatments, which may significantly impact on…
10 Mins
6 Dec 2018

Genomic Profiling Clinical Trials in Cancer of Unknown Primary

Cancer of unknown primary (CUP) accounts for 3–5% of all cancers, and prognosis is poor for most patients, with a median survival of 6–9 months…
EMJ
6 Dec 2018

Dr Mohammad Akheel

Consultant Head and Neck Oncosurgeon, Greater Kailash Hospitals, Indore, India…
1 Mins
6 Dec 2018

New Immunotherapy Approaches for The Treatment of Cancer: Reported at the European Society for Medical Oncology Congress 2018

Immunotherapy is currently a pillar in the treatment of cancer, in addition to surgery, radiotherapy, chemotherapy, and molecular-targeted therapies.
13 Mins
6 Dec 2018

Editor's Pick: Novel Targets and Therapies in T Cell Lymphoma

This review presents the recent advances in our understanding of the cellular pathogenesis of T cell non-Hodgkin lymphoma (NHL) and the potential of…
2 Mins
6 Dec 2018

Major Determinants of Delayed Access to Innovative Medicines for Metastatic Melanoma: The Results of the Melanoma World Society (MWS) and European Association of Dermato-Oncology (EADO) Survey

At the 2018 European Society for Medical Oncology (ESMO) Congress in Munich, Germany, the Melanoma World Society (MWS) and European Association of…
12 Mins
6 Dec 2018

Recent Advances in the Treatment of Metastatic Soft Tissue Sarcoma

Soft tissue sarcomas (STS) are a rare group of heterogeneous malignancies with >50 histologic subtypes that have varying biological behaviour and…
We’ve noticed you’re accessing
from North/South America.